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Abstract
Background: The past 2 decades have seen an increased incidence of head and neck
squamous cell carcinoma (HNSCC) in a nontraditional, low-risk patient population
(ie, 45 years of age, no substance use history), owing to a combination of human
papillomavirus (HPV) infection and individual genetic variation.
Methods: Articles positing genetic variants as contributing factors in HNSCC inci-
dence in low-risk, nontraditional patients were identified using a PubMed search,
reviewed in detail, and concisely summarized herein.
Results: Recent data suggest that common polymorphisms in DNA repair enzymes,
cell-cycle control proteins, apoptotic pathway members, and Fanconi anemia-
associated genes likely modulate susceptibility to HNSCC development in low-risk,
nontraditional patients.
Conclusion: At present, there is a lack of robust, comprehensive data on genetic
drivers of oncogenesis in low-risk patients and a clear need for further research on
genetic alterations underlying the rising incidence of HNSCC in low-risk, nontradi-
tional patients.
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1 | INTRODUCTION
Each year, approximately 600 000 incident cases of head and
neck squamous cell carcinoma (HNSCC) are diagnosed
worldwide, leading to >350 000 deaths.1 Cases of HNSCC
encompass malignancies of the upper aerodigestive tract (ie,
oral cavity, oropharynx, hypopharynx, and larynx) and classi-
cally afflicts older, white men with a heavy tobacco and/or
alcohol use history.2–4 In this population, chronic exposure to
carcinogens results in accumulation of somatic alterations in
an assortment of oncogenes (eg, PIK3CA), tumor suppressors
(eg, TP53, CDKN2A, and NOTCH1), and cell-cycle regulators
(eg, CCND1) that increase the risk of HNSCC over time.5
Despite the high prevalence of tobacco and alcohol use in the
general population, only a small proportion of individuals will
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ultimately develop HNSCC, indicating that genetic variants
may modulate susceptibility in individual patients.
Over the last 2 decades, there has been an increasing
prevalence of HNSCC in a nontraditional, low-risk patient
population (ie, 45 years of age, no substance use history).
A rapid rise in high-risk human papillomavirus (HPV)-asso-
ciated HNSCC accounts for the majority of these cases,6,7
although there remains a high-risk HPV-independent subset
of low-risk patients who lack identifiable etiological fac-
tors.8,9 The latter population is seen with particular frequency
in cancers of the oral cavity.10 Although differences in
genetic drivers of oncogenesis between these younger, low-
risk patients and their older, traditional counterparts require
further elucidation, current evidence suggests that clinical
outcomes (ie, disease-specific survival) are similar and com-
parably poor in these 2 patient groups.8,11
Recently, the International Head and Neck Cancer Epide-
miology (INHANCE) consortium aimed to compare the role
of family history of HNSCC, tobacco, and alcohol as onco-
logic risk factors among a large cohort of young (45 years)
and older (45 years) patients.12 Importantly, a higher pro-
portion of oral tongue and oral cavity cancers was seen in
young patients with HNSCC. Compared with older patients,
these cancers were found to be less attributable to tobacco
and alcohol use and had a higher association with a family
history of early onset HNSCC. As such, differences in
HNSCC etiology among low-risk, nontraditional patients and
their older counterparts are evident. The association of
HNSCC with family history in the setting of a weaker (or
absent) contribution from tobacco and alcohol suggests a
hereditary, germline component present in young patients
that is absent in the traditional HNSCC cohort.
Herein, we present an overview of the current landscape
of genetic determinants of HNSCC in low-risk patients, a
population defined by young patient age and status as non-
smokers/drinkers. We discuss genetic polymorphisms in
DNA repair enzymes and apoptotic pathway members, as
well as known heritable forms of HNSCC, specifically fami-
lial HNSCC, and Fanconi anemia-associated HNSCC. Addi-
tionally, we address genetic susceptibility to HNSCC in
relation to high-risk HPV serology, relevant to the soaring
national prevalence of viral infection and epidemiologic rise
in high-risk HPV-associated HNSCC. Finally, we conclude
with an acknowledgment of current barriers to the under-
standing of genetic determinants of HNSCC in low-risk
patients and implications for future research in this area.
1.1 | Genetic variants in DNA repair enzymes
in patients with low-risk head and neck
squamous cell carcinoma
Pathways for DNA damage repair fall into 3 broad categories
determined by the nature and extent of genomic damage:
(1) base excision repair; (2) nucleotide excision repair; and
(3) double-strand break repair. Perturbations in cellular DNA
repair pathways lead to genomic instability, aberrant cell
function, and unchecked replication, all of which can pro-
mote tumor development.13 Inherited diseases compromising
DNA repair pathways, such as Fanconi anemia (double-
strand break repair), xeroderma pigmentosum (nucleotide
excision repair), and BRCA1/2-associated cancer syndromes
(double-strand break repair) drastically increase an individu-
al’s lifetime risk of developing multiple cancers of different
sites.14 Functioning DNA repair machinery is essential to
combat the accumulation of tumor-promoting mutations
induced by chronic exposure to carcinogens in tobacco
smoke, as in the case of HNSCC.15 However, even in non-
tobacco users, polymorphisms in DNA repair genes may
underlie oncogenesis by compromising genomic integrity, as
clearly illustrated in the aforementioned hereditary syn-
dromes. Current evidence on the association of polymor-
phisms in genes of DNA repair pathways with risk of
HNSCC in low-risk patients is conflicting.
A systematic review and meta-analysis by Flores-
Obando et al16 examined associations in polymorphisms in
DNA damage response genes with the risk of HNSCC devel-
opment in 30 case-control studies comprising roughly 8000
patients with oral, pharyngeal, or laryngeal cancers and
12 000 matched controls. Focusing their analysis on DNA
repair enzymes in the nucleotide excision repair (XPA, XPD,
XPC, XPF, and ERCC1), base excision repair (XRCC1), and
double-strand break repair (XRCC3) pathways, the authors
reported an increased risk of HNSCC associated with muta-
tions in XPD codon 312 and XRCC1 codon 399 in white and
Asian populations and mutations in XRCC1 codon 194 solely
in Asian patients, although notably each of these associations
was only marginally statistically significant. An updated
meta-analysis with extensive subgroup stratification by
smoking status, HNSCC subsite, and ethnicity by Lou et al17
differed from Flores-Obando et al16 in that the XRCC1 codon
399 polymorphism had no significant impact on HNSCC
susceptibility among 7000 patients with HNSCC (compared
against 10 000 controls), alone or in an interactive fashion
with smoking. However, the authors did note that XRCC1
R194W homozygosity and tobacco use interacted to produce
a statistically significant increase in HNSCC risk in the
patients studied. Although these results failed to support a
clear susceptibility to HNSCC attributable to polymorphisms
in genes of DNA repair machinery, they do suggest that sub-
group stratification by smoking status may uncover correla-
tions within low-risk populations. A second response to
Flores-Obando et al16 found no link between XPD codon
312 polymorphism and HNSCC susceptibility in a meta-
analysis of 9 case-control studies totaling 2700 HNSCC
patients and 4500 controls.18 However, stratification by age,
smoking, or drinking status was not shown in this report,
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thus limiting the ability to interpret the data in the context of
these critical variables.
A recent genomewide association study of European
patients with HNSCC within the INHANCE consortium
identified a novel polymorphism at 4q21 (rs1494961) signifi-
cantly associated with susceptibility to HNSCC in the
roughly 2000 patients analyzed.19 This site is positioned
within the HEL308 gene, a DNA-dependent ATPase and
helicase important for DNA intra-strand cross-linking
repair.20 Sequencing of rs1494961 in an additional independ-
ent cohort of 5600 lung cancer cases and 9300 controls
showed that this polymorphism was associated with the risk
of lung cancer, suggesting that this variant may play an
important role in tobacco-associated cancers in general. On
subgroup stratification, the association of the rs1494961 vari-
ant with HNSCC risk was maintained in patients <50 years
of age, although was lost in never-users of tobacco or alco-
hol, precluding any definitive conclusions regarding the role
of rs1494961 in young patients with low-risk HNSCC. A
second genomewide association study by Liang et al21 iden-
tified a positive, multiplicative interaction between HEL308
polymorphisms and cigarette use of >70 pack-years in 600
HNSCC cases, signifying that this genetic variant is less rele-
vant to a low-risk, nontraditional patient population. Finally,
a follow-up genomewide association study of a relatively
small Chinese population with HNSCC revealed no associa-
tion between rs1494961 polymorphism and HNSCC suscep-
tibility (Table 1).16–19,21,22
Clearly, future confirmative studies and mechanistic
investigations are needed to clarify inconsistencies in these
posited associations between DNA repair polymorphisms
(eg, HEL308) and HNSCC in low-risk, nontraditional
patients. Such studies should stratify included HNSCC cases
and controls by relevant clinical factors, such as age, tobacco
use, and HNSCC subsite that may help uncover complicated
gene-by-gene or gene-by-environment effects and generate
robust, generalizable associations between polymorphisms in
DNA repair machinery and HNSCC in low-risk patients.
1.2 | Genetic variants in apoptotic pathway
members in patients with low-risk head and
neck squamous cell carcinoma
Programmed cell death by apoptosis serves as a critical bar-
rier to cancer development and progression.23 Apoptotic sig-
nals are cued by various physiological stressors (eg, DNA
damage and growth-factor deprivation) and trigger cellular
suicide by caspase cascade activation. Dysfunction in this
native defense mechanism promotes tumorigenesis and con-
fers metastatic potential and treatment resistance in cancer
cells.24,25 One of the key regulators of apoptosis is p53
(encoded by the TP53 gene), a tumor suppressor that induces
cell-cycle arrest and apoptosis in response to DNA damage,
oncogene activation, hypoxia, and numerous other stimuli.26
Loss-of-function mutation in TP53 is one of the most com-
mon acquired genetic events across all human cancers,
including HNSCC, in which whole-exome sequencing has
identified somatic silencing mutations in TP53 in over 70%
of tumors.5,27
In addition to acquired, tumor-promoting mutations in
TP53, there are 2 germline polymorphisms at codon 72 of
TP53 generating an arginine (p53Arg) or proline (p53Pro)
residue at this position that are common in the human popu-
lation.28 The p53Arg and p53Pro variants harbor minimal
conformational differences in protein structure, yet several
reports have posited that these polymorphisms may be
important determinants of response to chemotherapies and
differential oncologic outcomes.29–31 Intriguingly, HNSCC
cases have shown bias toward p53Arg homozygosity30 and
patients with this alteration respond less favorably to
platinum-based chemoradiotherapy, perhaps due to negative
influence of p53Arg on p73-dependent initiation of apopto-
sis.31 At present, however, potential influences of p53 poly-
morphisms on HNSCC susceptibility alone, particularly in
low-risk patients, have yet to be investigated.
The p53 upregulated modular of apoptosis (PUMA) plays
a similar crucial role in promoting apoptosis through interac-
tion with the antiapoptotic Bcl-2. PUMA expression is upreg-
ulated by p53, although likely has both p53-dependent and
p53-independent roles in HNSCC as the expression of
PUMA is sufficient to prevent HNSCC growth in vitro
regardless of p53 mutational status.32 At present, no somatic
mutations within coding regions of PUMA have been identi-
fied in HNSCC, although 2 polymorphisms (rs3810294 and
rs2032809) in the gene’s promoter region have been pro-
posed as potential risk factors for incident HNSCC in white
populations.33 These polymorphisms may result in differen-
tial binding affinities of transcription factors to the PUMA
promoter, although the consequential effect on PUMA
expression is still unclear. In a cohort study of 380 HNSCC
cases and 335 controls, increased HNSCC risk was seen in
patients with HPV16 seropositivity and a variant PUMA
gene, an effect modification that was particularly pronounced
in never-smokers, never-drinkers, young patients (<58
years), and in oropharyngeal subsites.33 Mechanistically, the
HPV16 E6 oncoprotein subverts apoptosis in infected cells
by interfering with the p53/PUMA/Bax cascade, although
functional evidence of any direct interaction between PUMA
and E6 has yet to be elucidated.34
Last, polymorphisms in the promoter of baculoviral
inhibitor of apoptosis repeat-containing 5 (BIRC5; also
known as survivin) gene, have been implicated as risk factors
for the development of HNSCC in Asian populations.35 In
HNSCC in vitro models and primary tumors, somatic muta-
tions and overexpression of BIRC5 correlates with resistance
to conventional chemoradiotherapy,36,37 although how the
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promotor polymorphisms (at present, 5 identified in the oral
cavity38 and 1 in nasopharyngeal carcinoma39) relate to
BIRC5 expression has not yet been evaluated. Importantly,
of currently identified BIRC5 promoter polymorphisms, there
is conflicting evidence on their association with HNSCC in
low-risk patients. One investigation found that these poly-
morphisms confer elevated HNSCC risk in nonsmoking,
nondrinking populations,39 whereas another found that
BIRC5 variants confer susceptibility to HNSCC only in an
interactive fashion with betel quid chewing or tobacco use.38
These opposing conclusions highlight the need for further
studies examining the association of genetic variants in apo-
ptotic pathways with HNSCC in low-risk patients from mul-
tiple independent cohorts.
1.3 | Familial/hereditary head and neck
squamous cell carcinoma
The vast majority of HNSCC are sporadic cancers, attribut-
able to known etiologic factors, such as tobacco, alcohol,
and HPV. At present, there is a paucity of data on the possi-
ble role of family history and importance of inheritance
TABLE 1 Summary of DNA repair pathway gene polymorphisms investigated in low-risk, non-traditional patients with head and neck
squamous cell carcinoma
Gene investigated Study design
Case/control
size
Strength of
HNSCC association
OR (95% CI)
Subgroup
stratification
XRCC1 R194W
(homozygous)
Meta-analysis of 30 studies
(Flores-Obando et al16)
7291/12 052 1.78 (1.13-2.82) Asians
Meta-analysis of 29 studies
(Lou et al17)
6719/9627 0.91 (0.77-1.08) N/A
(total population)
2.53 (1.16-5.53) Smokers
XRCC1 R399Q (homozy-
gous and heterozygous)
Meta-analysis of 30 studies
(Flores-Obando et al16)
7291/12 052 1.14 (1.01-1.27) Whites
Meta-analysis of 29 studies
(Lou et al17)
6719/9627 0.99 (0.90-1.09) N/A
(total population)
0.7 (0.43-1.15) Smokers
XPD D312N (heterozygous) Meta-analysis of 30 studies
(Flores-Obando et al16)
7291/12 052 1.14 (1.01-1.29) N/A
(total population)
Meta-analysis of 9 studies
(Hu et al18)
2670/4452 1.11 (0.99–1.24) N/A
(total population)
HEL308 (homozygous and
heterozygous)
Genomewide association study of
European Studies in INHANCE
Consortium
(McKay et al19)
8605/16 226 1.13 (1.08-1.17) N/A
(total population)
1.19 (1.08-1.31) Age <50 y
1.03 (0.93-1.14) Never smokers
1.04 (0.93-1.18) Never drinkers
HEL308 (homozygous) Case control study of patients in
the Boston, MA area
(Liang et al21)
575/676 0.78 (0.57-1.06) N/A
(total population)
Case control study of Chinese
Nationals
(Yuan et al22)
397/900 0.98 (0.82-1.18) N/A
(total population)
Abbreviations: CI, confidence interval; HNSCC, head and neck squamous cell carcinoma; INHANCE, International Head and Neck Cancer Epidemiology; N/A, not
applicable; OR, odds ratio.
Figure text in boldface indicates statistical significant.
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patterns in HNSCC risk, particularly in low-risk patients.
Previously mentioned herein, a 2015 INHANCE consortium
study analyzed risk factors for incident HNSCC among 25
case-control studies and identified a convincing association
between family history of early onset cancer and incident
HNSCC in ever-smokers <45 years of age (odds ratio [OR]
2.27; 95% confidence interval [CI] 1.26-4.10).12 This associ-
ation was not present among older (45 years) patients with
HNSCC (OR 1.10; 95% CI 0.91-1.31). Interestingly, an ear-
lier INHANCE case-control study examining 9000 patients
with HNSCC and 14 000 healthy controls similarly found
that a family history of HNSCC in a first-degree relative con-
ferred an increased risk of incident HNSCC in the patients
examined (OR 2.2; 95% CI 1.6-3.1 for siblings and OR 1.5;
95% CI 1.1-1.8 for parents).40 Importantly, this relationship
was markedly stronger among patients with HNSCC with
positive family history and tobacco and alcohol use (OR 7.2;
95% CI 5.5-9.5). These studies suggest that a familial/heredi-
tary component to HNSCC may be attributable to inherited
sensitivity toward tobacco-related and alcohol-related carci-
nogens, thus, this relationship is less relevant to a low-risk,
never-smoker/never-drinker HNSCC population.
Inherited mutations in the CDKN2A gene, encoding the
important tumor suppressor and cell-cycle regulating protein
p16/INK4A, have been implicated in familial syndromes con-
ferring a significantly increased lifetime risk of melanoma,
pancreatic, lung, and breast cancer as well as of HNSCC.41,42
Although the literature is limited, 2 recent case reports identi-
fied germline CDKN2A mutations in probands with HNSCC
and melanoma among an extensive family history.43,44 In the
first, a novel single-nucleotide deletion (c.106delG) resulted
in a premature stop codon (p.Ala36ArgfsX17).43 In the sec-
ond, a missense mutation (G302T) at exon 2 of CDKN2A
with loss of heterozygosity was implicated.44 A third
CDKN2A germline variant termed p16-Leiden results in a 19-
nucleotide deletion (c.225_243del19) and significantly
heightens the lifetime risk of HNSCC development (relative
risk 18.8; 95% CI 6.05-58.2).45 Inherited CDKN2A loss-of-
function mutations clearly elevate HNSCC risk in low-risk,
never-smokers. Again, however, the risk of HNSCC in
CDKN2A mutation carriers is amplified even more in ever-
smokers, suggesting that such mutations may impair carcino-
gen metabolism and is, thus, less relevant to a low-risk
HNSCC population.46
Nasopharyngeal carcinoma (NPC) is a poorly differenti-
ated squamous cell carcinoma (SCC) of the posterior naso-
pharynx with a well-documented propensity for familial
clustering.47 A review of candidate-gene approaches and
genomewide association studies to identify genomic loci
conferring increased NPC risk by Bei et al48 identified
ITGA9 at chromosome 3p, HLA-B/C and MICA at chromo-
some 6p, and CKDN2A/B at chromosome 9q. A second
study by Xiong et al49 supported a link between familial
variants in tumor suppressor gene clusters at chromosome
3p21 and NPC risk. Although further studies validating these
findings have yet to be performed, it stands to reason that
such germline variants likely contribute to NPC development
in younger patients who lack identifiable risk factors.
1.4 | Fanconi anemia association in patients
with low-risk head and neck squamous cell
carcinoma
Fanconi anemia is an inherited bone marrow failure syn-
drome caused by biallelic inactivation of 1 of 17 genes
(FANCA to FANCQ) inherited in an autosomal recessive or
x-linked recessive pattern.50 The FANC genes normally
encode proteins that maintain genomic stability by repairing
interstrand crosslinks (ICLs) in DNA (see Figure 11,50–52).
With an incidence of roughly 1 in 100 000 to 250 000 births,
Fanconi anemia leads to a spectrum of phenotypic abnormal-
ities that include congenital malformations (eg, short stature
and microcephaly) and cytopenias.53,54 Patients with Fanconi
anemia are also particularly susceptible to development of
malignancies, including leukemia, esophageal cancer, and
HNSCC. The risk of HNSCC in Fanconi anemia, particularly
of the oral cavity, is elevated roughly 500 to 700 times over
the general population.55 The median age of onset of
HNSCC in patients with Fanconi anemia is a young 33 years
of age and the vast majority (roughly 84%) of these patients
are never-smokers/never-drinkers, suggesting minimal envi-
ronmental contribution to HNSCC risk.56
Investigation into the association between Fanconi ane-
mia and HNSCC begets questioning of whether inherited or
sporadic FANC mutations may drive HNSCC development
in low-risk, nontraditional patients without Fanconi anemia.57
Tremblay et al58 confirmed lower expression of FANCA and
FANCG in oral cavity xenografts from young patients (<40
years), patients with HNSCC without Fanconi anemia as
compared to an older patient (>60 years) cohort and healthy
controls. The authors posited that attenuated expression of
FANCA and FANCG may explain mechanistic differences in
tumorigenesis between young, low-risk patients and their tra-
ditional HNSCC counterparts through defective carcinogen
metabolism or DNA repair capabilities. Recently, Chandrase-
kharappa et al screened 417 patients for germline Fanconi
anemia mutations in patients with head and neck cancer
under the age of 50 years. They identified that 44% of the
patients had the Fanconi anemia gene variants with 26% hav-
ing variants predicted to be damaging. Additionally, they
identified an increased mutational burden among 3 Fanconi
anemia genes (FANCD2, FANCE, and FANCL) relative to
the normal population; all of which are associated with other
malignancies [PMID: 286978401]. Additionally, a recent
investigation59 utilizing 17 HNSCC cell lines found that
FANC inactivation promotes genomic instability and
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tumorigenesis in only a small minority of non-Fanconi ane-
mia HNSCC, prompting other authors to posit epigenetic
modifications of FANC genes as potential drivers of sporadic
HNSCC in patients with non-Fanconi anemia.60,61
Transcription of FANC genes seems to be regulated in
synchrony with the cell cycle, as E2F, Rb, and ATR modu-
late expression of Fanconi anemia pathway components in
human cancer cell lines.62 Additionally, FANC-encoded pro-
teins form complexes with the products of BRCA1/2 genes
(implicated in hereditary breast and ovarian cancer) to exert
their ICL-repair functions.63,64 In future studies, mutational
status of upstream and downstream components of the Fan-
coni anemia pathway must be considered when clarifying
associations between FANC aberrations and HNSCC risk in
nontraditional patients.
Analysis of a 528-patient cohort of HNSCC cases from
The Cancer Genome Atlas (TCGA) dataset using cBioPortal
failed to demonstrate a consistent correlation between altera-
tions in FANC genes and HNSCC (Figure 11,50–52 and Table
265,66). However, only 42 of these 528 patients (8.0%) with
HNSCC were <45 years of age, so drawing definitive con-
clusions regarding genetic profiling in low-risk, nontradi-
tional patients with HNSCC is challenging. Despite the
rising prevalence of a young, low-risk HNSCC population,
the lack of genomic data from these patients precludes identi-
fication of causative genetic associations, prediction of clini-
cal outcomes, and trials of personalized therapeutics.
The association between patients with HNSCC and Fan-
coni anemia, as well as the association between altered
FANC genes and non-Fanconi anemia, low-risk patients with
FIGURE 1 Interstrand crosslinking (ICL) repair pathway defective in patients with Fanconi anemia (the Figure is based onmodels put forth by
Wang et al,50 Ceccaldi et al,51 and Garner et al52). A, ICL occurs. B, Fanconi anemia nuclear core complex (FACC) is a large, multi-subunit, E3 ubiquitin
ligase (enzymatic activity provided by FANCL). The FACC is recruited to the site of ICL detected by stalled replication fork. The FANCM activates ATR
serine/threonine kinase (ATR) via phosphorylation. The ATR functions downstream to phosphorylate FANCI in the ID complex.Manymodels propose
BRCA1 associates with the initial FACC to assist with CMG helicase removal, allowing the replication fork to approach the ICL site more closely. C, The
FACC recruits the phosphorylated Fanconi anemia ID complex (FANCI and FANCD2), and the FACCmono-ubiquitinates the Fanconi anemia ID com-
plex. D, Nucleolytic “unhooking” of the ICL occurs through recruitment of downstream nucleases FAN1 (no mutations are currently identified in patients
with Fanconi anemia), and multi-subunit FANCP(SLX4)/FANCQ(XPF). The FAN1 binds mono-ubiquitinated FANCD2. The FNACP(SLX4) contains
ubiquitin binding sites and potentially interacts with FANCD2 as well. The role behind association of multiple nucleases, and their individual significance
in nucleolytic processing, is unclear.51 E, Translesion synthesis (TLS) is performed by TLS-specific polymerases that are recruited to the nuclear foci. Mul-
tiple TLS polymerases have been implicated, including REV1 and POLf.51 Nomutations in TLS-specific polymerases have been identified in patients
with Fanconi anemia to our knowledge.1 F, Homologous recombination repair occurs through the recruitment of many repair factors. These include the
FANCN(PALB2)/FANCD1(BRCA2)/FANCO(RAD51C) complex and FANCS(BRCA1)/FANCJ(BRIP1), which functions as a helicase and inhibitor of
nonhomologous end joining. G, DNA has been successfully repaired by components in the Fanconi anemia pathway [Color figure can be viewed at
wileyonlinelibrary.com]
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HNSCC is in need of further characterization. To our knowl-
edge, there has been limited investigation into the association
of FANC genes with HNSCC in non-Fanconi anemia
patients, with even fewer of these analyses considering low-
risk patients specifically. In future mechanistic investigations
of the Fanconi anemia pathway in HNSCC, it will be impor-
tant to differentiate between somatic and germline mutations
in FANC within non-Fanconi anemia patients with HNSCC.
1.5 | E2F Polymorphisms in patients with
low-risk head and neck squamous cell
carcinoma
The E2F family of transcription factors play a central role in
modulation of cell-cycle progression and DNA synthesis and
repair.67 In quiescent cellular states, the Rb tumor suppressor
protein (Rb) binds to E2F, preventing it from activating tran-
scription machinery.68 In the absence of Rb, or when Rb is
sequestered by the HPV oncogenic protein E7, E2F becomes
free to facilitate transcription of target genes that modulate
the G1/S transition.69 Dysregulation of the Rb-E2F pathway
is seen almost universally across all human cancer types.
A recent investigation into the association of common
polymorphisms in E2F1 and E2F2, respectively, in 1100
HNSCC cases and 1090 healthy controls sought to correlate
these genotypes with susceptibility to incident HNSCC.70
The authors identified a statistically significant dose-
response relationship conferring increased risk of incident
HNSCC in patients harboring a greater number of these
unique genetic variants (OR 1.62; 95% CI 1.14-2.30 for indi-
viduals with 9 to 10 polymorphisms versus individuals with
0 to 4; P 5 .045). Importantly, the joint effect of multiple
E2F polymorphisms was particularly pronounced among
adults <57 years of ages (OR 1.74; 95% CI 1.07-2.85),
never-smokers (OR 1.85; 95% CI 1.07-3.17), never-drinkers
(OR 2.19; 95% CI 1.22-3.95), and those with a family his-
tory of cancer in a first-degree relative (OR 1.64; 95% CI
1.05-2.57). These results suggest a convincing, additive
effect of genetic variation within E2F genes on HNSCC risk,
with enhancement of susceptibility in low-risk patients.
The authors of a recent investigation hypothesized that a
common polymorphism (rs3213180) in the 30UTR micro-
RNAs (miRNAs) binding site of E2F1 would be associated
with the risk of oral cavity and oropharyngeal SCC and HPV
status of oropharyngeal SCC, given the aforementioned role
of HPV E7 in the Rb-E2F pathway.71 Patients with E2F1
rs3213180 polymorphism had an increased risk of develop-
ing oral cavity and oropharyngeal SCC (OR 3.3; 95% CI
2.4-4.6) regardless of HPV status. In individuals with HPV
seropositivity and this E2F1 polymorphism, never-smokers/
drinkers had a particularly pronounced risk of oropharyngeal
SCC compared to ever-smokers/drinkers (7.5-fold increased
risk in never-smokers vs ever-smokers, and 4.9-fold
increased risk in never-smokers vs ever-drinkers). In con-
trast, HPV seronegative individuals with E2F1 polymor-
phisms had a similar risk of oral cavity and oropharyngeal
SCC when comparing subsets of never-smokers/drinkers to
ever-smokers/drinkers (0.97-fold decreased risk in never-
smokers vs ever-smokers and 0.8-fold decreased risk in
never-drinkers vs ever-drinkers). These complex interactions
suggest that HNSCC susceptibility in HPV-positive, never-
smokers/drinkers is due, at least in part, to specific interac-
tions between variant E2F1-encoded proteins and the HPV
E7 oncogene.
1.6 | Patients with high-risk human
papillomavirus and low-risk head and neck
squamous cell carcinoma
The incidence of high-risk HPV-associated HNSCC, particu-
larly of oropharyngeal subsites, has soared in recent years
and is most often seen in patients who lack traditional risk
factors, namely tobacco and alcohol use.6,72,73 Progression
TABLE 2 Alteration frequency of Fanconi anemia pathway and
Fanconi anemia pathway-associated genes within the 528-patient The
Cancer Genome Atlas head and neck squamous cell carcinoma provi-
sional dataset retrieved using cBioPortal65,66 [Color table can be
viewed at wileyonlinelibrary.com]
Gene (alias)
No. of cases
altered
(504 total)
Percent
of cases
altered
Fanconi anemia pathway
FANCA 11 2.20
FANCB 18 4
FANCC 13 2.60
FANCD1 (BRCA2) 27 5
FANCD2 13 2.60
FANCE 3 0.60
FANCF 5 1
FANCG 26 5
FANCI 9 1.80
FANCJ (BRIP1) 15 3
FANCL 6 1.20
FANCM 14 2.80
FANCN (PALB2) 8 1.60
FANCO (RAD51C) 3 0.60
FANCP (SLX4) 10 2
FANCQ (ERCC4) 5 1
FANCS (BRCA1) 13 2.60
Fanconi anemia pathway-associated
BRCA2 27 5
BRCA1 13 2.60
RB 28 6
ATR 76 15
Color-coding of the genes in the table corresponds to the color-coding of gene
products in Figure 1 depicting the Fanconi anemia-pathway.
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from oropharyngeal HPV infection to malignancy takes in
excess of a decade and occurs in a small but significant
minority of patients, indicating that genetic variation among
individuals may play a pivotal role in differential risk of
malignant transformation.74,75
Transforming growth factor-beta (TGF-b) is an anti-
inflammatory cytokine with important roles in inflammation
and immune responses that ultimately lead to HPV clearance
or immune evasion and viral persistence.76 Three distinct
polymorphisms in the TGF-b gene (C509T, T869C, and
G915C) have been shown to increase plasma levels of circu-
lating TGF-b in human subjects.77 As TGF-b suppresses
proinflammatory responses mediated by Th1 and Th2 lym-
phocytes, elevated TGF-b levels may compromise immune
surveillance and control of HPV-infected cells.78 This immu-
nosuppressive effect may be augmented by HPV-induced
transcription of immunosuppressive cytokines, including
TGF-b, as has been shown in cervical cancer models.79 As
such, Guan et al80 hypothesized that TGF-b polymorphisms
may contribute to differential genetic susceptibility to high-
risk HPV-associated HNSCC. The authors genotyped TGF-b
polymorphisms and confirmed HPV16 status in 200 primary
tumors of the oropharynx. Patients with variant TGF-b
genotypes were more than twice as likely to have an
TABLE 3 Alteration frequency of genes examined within this review, as reported in The Cancer Genome Atlas cohort and in Morris et al,95 a
precision oncology sequencing study of recurrent and metastatic head and neck squamous cell carcinoma from Memorial Sloan Kettering Cancer
Center
TCGA HNSCC cohort5
(504 cases) Morris et al95 (132 cases)
Gene (alias)
No. of cases
altered
Percent of
cases altered
No. of
cases altered
Percent of
cases altered
DNA repair genes
XRCC1 5 1 0 0
XPD (ERCC2) 7 1.4 2 1.5
HEL308 (HELQ) 10 2 0 0
Apoptosis related
TP53 363 72 62 47
PUMA (BCC3) 1 0.2 0 0
BIRC5 0 0 0 0
Familial HNSCC related
CDKN2A 270 54 32 24
CDKN2B 143 28 10 8
ITGA9 6 1.2 0 0
HLA-B 24 5 0 0
HLA-C 5 1 0 0
MICA 6 1.2 0 0
Cell-cycle related
E2F1 17 3 0 0
E2F2 4 0.8 0 0
HPV associated
MDM2 24 5 3 2.3
MDM4 5 1 0 0
MCL1 13 2.6 9 7
NOXA (PAIMP1) 22 4 1 0.8
PUMA (BBC3) 1 0.2 0 0
TFGB1 4 0.8 0 0
TP53 363 72 62 47
TP73 8 1.6 0 0
Abbreviations: HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; TCGA, The Cancer Genome Atlas.
Many of these genes had high alteration rates (eg, TP53, CDKN2A), although those postulated to enhance HNSCC susceptibility in low-risk patients were less com-
monly altered in the overall TCGA cohort. The HNSCC TCGA provisional cohort had very few younger, low-risk patients (42 individuals were 45 years of age
at diagnoses.
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HPV16-positive tumor (OR 2.28; 95% CI 1.16-4.50) com-
pared with patients with wild-type TGFb. Furthermore, a
stratified analysis showed enhancement of this association
among patients <54 years of age (OR 4.07; 95% CI 1.52-
10.9), never-smokers (OR 3.76; 95% CI 1.15-12.3), and
never-drinkers (OR 5.01; 95% CI 1.03-24.3). Similarly, 4
common polymorphisms (rs1800629, rs1799724, rs1800630,
and rs1799964) in the gene promoter for tumor necrosis
factor-alpha, a versatile proinflammatory cytokine involved in
viral defense, have been proposed as susceptibility biomarkers
for HPV16-associated oropharyngeal cancers in young, never-
smokers/drinkers.81 Finally, intriguing preliminary reports
suggest that functional genetic polymorphisms of miRNAs
likely contribute to variations in miRNA-mediated immune
function and inflammation crucial for antiviral defense.82,83
Taken together, the aforementioned studies provide evidence
that genetic variation in immune-related genes augments the
risk of high-risk HPV-mediated malignant transformation,
particularly in young, low-risk HNSCC populations.
The critically important tumor suppressor p53 has been
called the “guardian of the genome” for its role in activation
of DNA repair pathways and initiation of growth arrest and
apoptosis in response to genomic instability.84 Inactivating
TP53 gene aberrations are oncogenic drivers in the vast
majority of HNSCC and portend worse oncologic out-
comes.5,27 The HPV E6 oncoprotein complexes with human
E6-associated protein to ubiquitinate p53, leading to its pro-
teasomal degradation, a necessary cellular process for HPV-
mediated carcinogenesis. As discussed above, a common
polymorphism is observed at codon 72 of p53, replacing an
arginine residue with proline; this amino acid change may
influence the protein’s susceptibility to E6-mediated degrada-
tion.85 Variant genotypes at this p53 locus enhance suscepti-
bility to oropharyngeal cancers in an interactive and
multiplicative fashion with HPV16 seropositivity and never-
smoking status (OR 22.5; 95% CI 4.8-106.2).85 Two linked
polymorphisms (G4C14-to-A4T14) in exon 2 of p73, a close
family member of p53 that activates the promoter of several
p53-responsive genes, confers similarly enhanced suscepti-
bility to oropharyngeal cancers in HPV16-positive, never-
smokers/drinkers.86 Young (ie, <50 years), HPV16-positive
individuals who harbor combined variants in both p53 and
p73 and are never-smokers/drinkers have an even greater
risk of incident oropharyngeal cancers.87–89 Finally, MDM2
and MDM4 promoter polymorphisms synergize with HPV
seropositivity to increase oropharyngeal cancer risk in young,
never-smokers/drinkers.90,91 MDM2 and MDM4 are p53-
pathway members that inhibit p53-mediated transcriptional
activity and target p53 for proteasomal degradation, thus
inhibiting DNA damage repair, cellular growth arrest, and
apoptosis.91
Components of the intrinsic apoptotic pathway may also
be important contributors to differential risk of
oropharyngeal cancer in young, HPV16-positive, never-
smokers/drinkers. Overexpression of Mcl-1 and deficiency of
NOXA, antiapoptotic and proapoptotic members of the Bcl-2
family, respectively, offer p53-dependent protection from
apoptosis in multiple myeloma models, although confirma-
tory studies of this relationship in HNSCC are lacking.92,93
Genetic variants in Mcl1 and NOXA promoter regions may
render cells more susceptible to HPV E6-mediated interfer-
ence with the p53-NOXA-Mcl1 axis. To test this hypothesis,
Zhou et al94 analyzed 4 functional polymorphisms in the
NOXA (rs9957673 and rs45589496) and Mcl-1 (rs9803935
and rs3738485) promoters in 372 cases of oropharyngeal
cancer and 315 healthy controls. Their results suggested a
joint effect on oropharyngeal cancer risk in young, never-
smoking/drinking patients with multiple NOXA/Mcl-1 poly-
morphisms and HPV16 seropositivity.
2 | CONCLUSIONS
The rise in the number of low-risk, nontraditional patients
with HNSCC in recent years should be met with a spirited
effort to characterize novel germline and somatic genomic
events that drive oncogenesis in this population. The current
literature provides preliminary evidence of risk variants that
may contribute to HNSCC development in low-risk patients,
although conclusions are limited by conflicting findings, lack
of consistent subgroup stratification, and small sample sizes.
Moving forward, we postulate that germline alterations
in genes, such as BRCA1, p53, and E2F, which are impli-
cated as oncologic drivers after somatic inactivation across
human cancers, are likely to be ubiquitous and strongly con-
served among young, low-risk HNSCC cases (Table 335).
Dedicated investigation of genetic aberrations in large popu-
lations of low-risk, nontraditional patients with HNSCC is
imperative to advance our understanding of mechanisms of
carcinogenesis, risk-stratify patients, and improve oncologic
outcomes in this population. Alternatively, HNSCC develop-
ment in low-risk patients may reflect exposure to unknown
environmental factors, unclassified carcinogens, or a more
complex interplay between multiple environmental influen-
ces and genetic variation.
Identifying pathogenic alterations in the low-risk
HNSCC population will improve efforts to combat cancer
progression. These studies may allow identification of at-risk
patients from an early age, leading to subsequent modifica-
tion of environmental and lifestyle factors, and may precede
the development of novel, targeted therapies. Further
research on low-risk, nontraditional patients with HNSCC is
necessary and will ideally reveal a combination of actionable
genetic drivers and modifiable lifestyle or environmental risk
factors, thereby providing a means to reduce the prevalence,
morbidity, and mortality of this disease.
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